LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Accueil・Liste d'Actions・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Fermé

16.72 -1.12

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

16.63

Max

17.45

Chiffres clés
By Trading Economics
Revenu	-6.4M -20M
Ventes	-807K 71M
BPA	-0.13
Marge bénéficiaire	-28.24
Employés	624
EBITDA	-7.9M -14M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+19.35% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	121M 2.4B
Ouverture précédente	17.84
Clôture précédente	16.72

Adaptive Biotechnologies Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 juin 2026, 22:20 UTC

Acquisitions, Fusions, Rachats

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 juin 2026, 15:41 UTC

Principaux Mouvements du Marché

American Battery Shares Jump on Energy Department Victory

8 juin 2026, 23:46 UTC

Market Talk

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 juin 2026, 23:37 UTC

Market Talk

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 juin 2026, 23:25 UTC

Market Talk

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 juin 2026, 23:25 UTC

Market Talk

Global Equities Roundup: Market Talk

8 juin 2026, 21:57 UTC

Acquisitions, Fusions, Rachats

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 juin 2026, 21:56 UTC

Acquisitions, Fusions, Rachats

Salesforce Agrees to Buy m3ter

8 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8 juin 2026, 19:22 UTC

Market Talk

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 juin 2026, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 juin 2026, 18:52 UTC

Market Talk

Global Energy Roundup: Market Talk

8 juin 2026, 18:52 UTC

Market Talk

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 juin 2026, 18:17 UTC

Market Talk

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 juin 2026, 17:32 UTC

Market Talk

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 juin 2026, 17:29 UTC

Market Talk

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 juin 2026, 17:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 juin 2026, 16:55 UTC

Acquisitions, Fusions, Rachats

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 juin 2026, 16:54 UTC

Acquisitions, Fusions, Rachats

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 juin 2026, 16:40 UTC

Market Talk

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 juin 2026, 16:31 UTC

Market Talk

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 juin 2026, 16:27 UTC

Market Talk

Mexican Inflation Seen Easing in May -- Market Talk

8 juin 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 juin 2026, 16:03 UTC

Acquisitions, Fusions, Rachats

Orange Bought Stake From Lorca

8 juin 2026, 16:01 UTC

Acquisitions, Fusions, Rachats

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 juin 2026, 16:01 UTC

Acquisitions, Fusions, Rachats

Orange Acquires 100% Ownership of MasOrange

8 juin 2026, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

8 juin 2026, 15:58 UTC

Market Talk

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 juin 2026, 15:55 UTC

Market Talk

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 juin 2026, 15:41 UTC

Market Talk

Gold Falls Below 200-Day Moving Average -- Market Talk

Comparaison

Variation de prix

Adaptive Biotechnologies Corp prévision

Objectif de Prix

By TipRanks

19.35% hausse

Prévisions sur 12 Mois

Moyen 20.17 USD 19.35%

Haut 22 USD

Bas 18 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

8 ratings

Achat

Maintien

Vente

Basé sur 8 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.